Washington. The proposed sponsored research agreement between Scripps Research Institute and the Sandoz drugs company, which provoked widespread controversy when it was announced last year, was anomalous and is unlikely to be replicated elsewhere, according to Sandy Chamblee, acting deputy director of the US National Institutes of Health (NIH).
But whether the problems caused by such sponsorship agreements are real (as the media tend to suggest) or not (as many scientists would claim), Congress told NIH to fix them after hearings last June before a subcommittee chaired by Ron Wyden (Democrat, Oregon). And the NIH is now taking steps to do so.
The $300-million agreement between Scripps and Sandoz was effectively blocked by NIH as a result of public concern that it would have given the company excessive control over the results of federally funded research.
But Chamblee told a meeting in Bethesda, Maryland last week of a panel convened to advise NIH on the future regulation of such agreements that a survey of 375 sponsored research deals across a hundred leading US research institutions found none of the others remotely close in either scale or scope to that proposed between Scripps and Sandoz.
Many scientists and industrialists involved in sponsored research agreements believe that most of them work to the public good. Universities have been actively encouraged to transfer technology to the private sector since the passage of the BayhDole act of 1980, which set the current framework for such agreements.
But, as the main source of public funds for biomedical research in the United States, the NIH pays for most work done at Scripps (and elsewhere). Congress-not unreasonably-wants NIH to ensure that the taxpayer is not being fleeced by agreements that give too much away to the industrial sponsors of other research projects carried out at these institutions.
Items that have generated concern include excessively broad agreements that encompass all areas of research, deals that exclude rival companies from access to unused ideas and provisions that restrict the freedom of researchers to publish and discuss their work.
The problem, as panel member Robert Merges, professor oflaw at Boston University, points out, is that NIH was not set up as a regulatory body, but is having to devise a policy that is both effective and simple to administer. "It's a tough goal," says Merges.
There is a range of views on how tight the guidelines need to be. Some advocate minimal interference. "We are doing this because someone asked us to, not because there's really an issue out there," says Donald Drakeman, chief executive of Medarex and an industrialist advising the panel.
But Paul Berg, professor of biochemistry at Stanford Medical Center, claimed that the current system is destroying pure, discovery-based science in US universities. "We sit here and talk about feeding ideas into American industry, but we ignore the price we will pay," he said.
Despite Berg's complaints, the predominant view on the NIH panel was that technology transfer under Bayh-Dole has been a big success, only temporarily blemished by the Scripps-Sandoz episode. But Congressman Wyden's subcommittee still expects NIH to provide some firm conflictof-interest rules for universities. Last week's panel discussion will lead to a report for an NIH internal task force led by Chamblee, which will in tum prepare draft guidelines for Harold Varmus, the director ofNIH, to take to his own advisory committee's next meeting in June.
The guidelines are expected to include a set of thresholds above which the university must obtain the approval of the NIH. Typical suggestions are that such approval should be sought for agreements worth more than $5 million, or involving more than one fifth of the work funded by NIH at a given institution.
Universities would retain responsibility for the details of smaller deals. But they would be reminded of their obligation to protect the academic freedom of their staff.
NIH hopes that by addressing the issue publicly, it can help to dispel uncomfortable memories ofthe Scripps-Sandoz affair, and show that most sponsored research agreements are working in the public interest.
Colin Macilwain
